Delveinsight Business Research 2020

What is Metastatic Pancreatic Cancer Market Size

in 2020?

Metastatic Pancreatic Cancer drug market

Pancreas is a gland which has two components exocrine component and

endocrine component. The exocrine component which is responsible for making
proteins/ enzymes and releasing them into small intestines for easy digestion.

On the other hand, the endocrine component of the pancreas is responsible for
making hormones and regulating the body’s metabolism.

According to the World Cancer Research Fund International, Metastatic

Pancreatic Cancer market research report, it is the 12th most commonly
occurring cancer in men and the 11th most in women.

Delveinsight Business Research

Delveinsight Business Research 2020

Metastatic Pancreatic Cancer Epidemiology

As per the American’s Cancer Society Cancer Facts and Figures report, by the end
of the year 2019, over 56,700 Americans will be diagnosed with pancreatic
cancer. The pancreatic cancer diagnosis rate has observed a 2% increase from the
last year.

Similarly according to a study conducted by Hall et al. an analysis of the clinical

trials over past thirty years in the US showed that approximately 84% of the
clinical trials were of metastatic pancreatic cancer and around 16% cases had
locally advanced pancreatic cancer.

The Cancer Research UK says that pancreatic cancer is the 11th most common
cancer in the United Kingdom, which accounts for three per cent of all new
cancer cases.

A review by Carrato et al., titled says that 80–90% of patients have an

unresectable tumour on diagnosis at an advanced stage in Europe.

Often times, the Metastatic Pancreatic Cancer Diagnosis is difficult owing to no

standard, cost-effective diagnostics tool. This results in the delayed screening of
pancreatic cancer, which eliminates surgical removal of the tumour as a viable
option. By the time, the pancreatic cancer is diagnosed, it has had spread all over
in the body.

Delveinsight Business Research

Delveinsight Business Research 2020

Metastatic Pancreatic cancer has the lowest survival rate of all the commonly
occurring cancers.

Metastatic Pancreatic Cancer drug market

Delveinsight Business Research

Delveinsight Business Research 2020

According to a study CONCORD-3, Pancreatic cancer has the lowest five-year

survival of around 6.9% in the UK.

As per the estimates presented by Cancer.net, if the pancreatic cancer is detected

at early stages the possible chances of 5-year survival rate is 34%. The sad part is
that only 10% of the patients are diagnosed at stage I.

The moment, pancreatic cancer spreads to surrounding parts of the body, the 5-
year survival rate reduces to 12%. Whereas, in the case of the tumour spreading
to distant parts of the body, the rate swoops down to 3%.

Pancreatic cancer is the seventh leading cause of deaths. And, its toll is rising.

Around 45,750 deaths are expected to be reported due to pancreatic cancer this
year. In America, a survey revealed that deaths due to pancreatic cancer
surpassed breast cancer. Unfortunately, soon a day will come when the
pancreatic cancer death ratio will overtake colorectal cancer.

Metastatic Pancreatic Cancer Therapeutics landscape

Pancreatic cancer treatment landscape depends on the stage and location of

cancer. To sum up, the primary aim of the treatment is always the elimination of
tumour. In case, the that is not possible, the focus revolves around improving the
quality life of the patients and preventing the growth of the tumour.

Metastatic Pancreatic Cancer Therapies

Metastatic Pancreatic cancer market report comprises surgery, targeted therapy,

radiation therapy, chemotherapy, immunotherapy and many times a combination
of therapies.

However, in case of metastasized or locally metastatic pancreatic cancers,

surgically removal of the cancer is not an option. In those cases, palliative or
supportive care is given to pancreatic cancer patients to provide the best comfort
and relieve symptoms and pain.

Delveinsight Business Research

Delveinsight Business Research 2020

Chemotherapy

Chemotherapy is a commonly preferred option for Metastatic Pancreatic Cancer.

At present, the standard chemotherapy drug for metastatic pancreatic cancer
treatment is Gemzar (Gemcitabine). Gemzar, approved in the year 1996, is,

Thus, considered an effective Pancreatic cancer treatment option. However, there

are some associated side-effects like fever, infection, and elevation of liver
enzymes are usually transient and easily manageable.

Erlotinib prevents the growth of the tumour by blocking the epidermal growth
factor receptor (EGFR). As a result, the US FDA granted approval to Erlotinib
(Tarceva) manufactured by

OSI Pharmaceuticals in 2004 as the first-line treatment of locally advanced,

unresectable or metastatic pancreatic cancer in combination with gemcitabine.
General side effects include skin rash similar to acne, diarrhoea, and fatigue.

Targeted Therapy

There exists a treatment method which targets a specific genetic change in the
genome. Larotrectinib (Vitrakvi) has been approved for pancreatic cancer which
has NTRK fusion as its cause.

These agents are targeted agents but other chemotherapeutic agents, like
Nab‐paclitaxel (Abraxane), Oxaliplatin (Eloxatin), Nanoliposomal irinotecan
(Onivyde), Irinotecan (Camptosar), and

Others are also used as first‐line, second‐line, and off‐label chemotherapeutic

agents for locally advanced or metastatic pancreatic cancer patients. However,
these agents are associated with major side effects.

Delveinsight Business Research

Delveinsight Business Research 2020

Radiation Therapy

Metastatic Pancreatic cancer radiation therapy is employed to kill the cancerous

cells via radiation in the form of X-rays.

A painless and well-planned pancreatic cancer treatment option harms as little as

possible to other healthy body tissue.

In the case of locally Metastatic pancreatic cancer, radiation therapy is usually

administered with chemotherapy.

Metastatic Pancreatic Cancer Drug Market

The current Metastatic Pancreatic cancer market disease is dependent on the

chemotherapeutic agents and targeted agents. However, due to various side
effects, there is a high demand for standard and efficient therapies that cause
minimal to no side effects.

Several companies are working to bring novel, innovative therapies in the

Pancreatic cancer therapeutics market.

Companies influencing Metastatic Pancreatic Cancer Market

Key Metastatic pancreatic cancer pharma players such as AB Science, Rafael

Pharma, Eleison Pharmaceuticals, Syncore Biotechnology, and others are
developing therapies for the treatment of patients with Metastatic Pancreatic
Cancer.

Delveinsight Business Research

Delveinsight Business Research 2020

Masitinib (AB Science), CPI‐613 (Rafael Pharma), Glufosfamide (Eleison

Pharmaceuticals), EndoTAG (SB05) (Syncore Biotechnology) along with other
compelling treatment options in the clinical trials is expected to increase the
overall market size of Metastatic Pancreatic Cancer.

Metastatic Pancreatic Cancer drug market

Metastatic Pancreatic Cancer Pipeline products

Devimistat

CPI‐613, also known as devimistat, is in Phase III clinical trials by the company
Rafael Pharma. This is a lipoate analogue targeting mitochondrial tricarboxylic
acid (TCA). The US FDA designated CPI‐613 as an orphan drug for pancreatic
cancer treatment.

Delveinsight Business Research

Delveinsight Business Research 2020

Another combination study of devimistat with mfolfirinox and gemcitabine with

nab‐paclitaxel is ongoing in different phases of a clinical trial. The drug has also
received approval for pivotal clinical trials in pancreatic cancer.

Masitinib

Another agent, Masitinib is a selective tyrosine kinase inhibitor. Moreover,

masitinib has also received orphan drug designation for pancreatic cancer from
both the European Medicine Agency (EMA) and the US FDA.

It is currently in Phase III clinical trial for development of Locally Advanced or

Metastatic Pancreatic Cancer Treatment.

Glufosfamide

A widely used chemotherapeutic agent, Glufosfamide (ifosfamide), is used with

greater specificity and a better safety profile, targeting metabolically active
tumors and hypoxic tumour regions. The therapy is currently being used on
patients who were previously administered with Gemcitabine.

At present in Phase III trials, Eleison owns exclusive worldwide rights to

glufosfamide, but has sublicensed marketing rights to leading pharmaceutical
companies in China and South Korea for the Chinese and South Korean Pancreatic
cancer therapy markets.

EndoTAG‐1

EndoTAG‐1 (SB05), an innovative composition of the established cytostatic drug

paclitaxel combined with neutral and positive lipids, is in Phase III trials.

SB05 is expected to prevent the formation of new tumour blood vessels and
inhibits tumour growth in patients with Metastatic Pancreas Cancer.

Delveinsight Business Research

Delveinsight Business Research 2020

Metastatic Pancreatic Cancer Market forecast analysis

The advancement in the medical sectors has helped the metastatic pancreatic
cancer patient pool to find an effective cure in the form of various therapies that
promise to kill the tumour from its root.

Pancreatic therapies that can successfully target cancer depending upon the
reason behind the origin of the tumor will surely expand the Metastatic
pancreatic cancer market size.

The launch of upcoming therapies such as Devimistat (Rafael Pharmaceuticals),

Masitinib (AB Science), Glufosfamide (Eleison Pharmaceuticals), EndoTAG‐1 and
(Syncore Biotechnology) are some of the potential upcoming therapies which will
soon compete to grab the major chunk of Metastatic Pancreatic Cancer
market share.

In conclusion, the progress in the medical sector, the development of innovative

diagnostics tools, rising metastatic pancreatic cancer prevalence, increasing
awareness among people, and upcoming pipeline therapies will advance the
metastatic pancreatic cancer market forward.

Delveinsight Business Research